KEAP1 and lung adenocarcinoma: Another study [28] investigated the prognostic value of STK11/KEAP1 mutations in an observational real-world lung adenocarcinoma cohort, and the results suggested that STK11/KEAP1 mutations are prognostic, not predictive biomarkers for immunotherapy.